7 参考文献
[1]Reaven GM. Banting Lecture,1988:role of insulin resistance in human disease. Diabetes,1988,37:1595- 1607.
[2]Definition,Diagnosis and Classiication of Diabetes Mellitus and Its Complications:report of a WHO consultation. Geneva,Switzerland:Department of Noncommunicable Disease Surveillance.
World Health Organization,1999.
[3] Kahn R,Buse J,Ferrannini E,et al. The metabolic syndrome:time for a critical appraisal:joint statement from the American Diabetes Association and the European Association for the Study
of Diabetes. Diabetes care,2005,28:2289- 2304.
[4]Grundy SM,James I,Cleeman JI,et al.Diagnosis and management of the metabolic syndrome.An American Heart Association/ National Heart,Lung,and Blood Institute Scientific Statement. Circulation,2005,112:2735- 2752.
[5]Executive summary of the third report of the National Choles -terol Education Program(NCEP)expert panel on detection,evaluation,and treatment of high blood cholesterol in adults(Adult
Treatment Panel Ⅲ). JAMA,2001,285:2468- 2497.
[6]中华医学会糖尿病分会代谢综合征研究协作组. 中华医学会糖尿病分会关于代谢综合征的建议. 中华糖尿病杂志,2004,12:156- 161.
[7] Alberti KG,Zimmet P,Shaw J,et al.The metabolic syndrome:a new worldwide definition.Lancet,2005,366:1059- 1062.
[8]中国成人血脂异常防治指南制定委员会.中国成人血脂异常防治指南. 中华心血管病杂志,2007,35:390- 419.
[9]Miranda PJ,Defronzo RA,Califf RM,et al.Metabolic syndrome:definition pathopysiology and mechanisms.Am Heart J, 2005,149:33- 45.
[10]Chen X,Igbal N,Boden G.The effects of free fatty acids on gluconeogenesisand glycopenolysis in normal swbjects. J Clin In-Vest,1999,103:365- 372.
[11]Tarcin O,Bajaj M,Akalin S.Insulin resistance,adipocyte biology,and thiazolidinediones:a review.Metabolic Syndrome and
Related Disorders,2007,5:103- 115.
[12]杨永祥,胡大一.代谢综合征及其心血管病危险性的研究进展2004,2:161- 163.
[13] Wellen KE,Hotamisligil GS.Obesity - induced in flammatory changes in adipose tissue.J Clin invest,2003,112:1785- 1788.
[14]Ridker PM,Buring JE,Cook NR,et al. C- reactive protein,the metabolic syndrome,and risk of incident cardiovascular events:an 8 years follow- up of 14719 initially healthy American women.
Circulation,2003,107:391- 397.
[15]Pladevall M,Singal B,Williams LK,et al.A sigle factor underlies the metabolic syndrome:a comfirmatory factor analysis.DiabetesCare,2006,29:113- 122.
[16]祝之明. 代谢综合征的诊断和治疗. 中华心血管病杂志,2004,12:1163- 1166.
[17] Isoman B,Almgren P,Tuomi T,et al.Cardiovascular morbidity and mortality associated with the metabolic syndrome.Diabetescare,2001,24:683- 689.
[18]朱中玉,高传玉,黄克钧,等. 代谢综合征对冠心病的预测价值. 中国心血管病研究杂志,2004,2:201- 203.
[19] Lindstrom J,Louheranta A,Mannelin M. The Finnish Diabetes Prevention Study (DPS):Lifestyle intervention and 3 - yearresults on diet and physical activity .Diabetes Care,2003,26:3230- 3236.
[20]Tuomilehto J,Lindstrom J,Eriksson JG,et al.Prevention of type diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.N Engl J Med,2001,344:1343- 1350.
[21] Robins SJ,Rubins HB,Faas FH,et al.Insulin resistance and cardiovascular events with low HDL cholesterol.The Veterans Affairs HDL Intervention Trial (VA - HIT).Diabetes Care,2003,26:1513- 1517.
[22]Rodriguez- Moctezuma JR,Robles- lopez G,Lopez- Carmona JM,et al. Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes Obes Metab,2005,7:189- 192.
[23] Stratton IM,Cull CA,Adler AI,et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes:a prospective observational study(UKPDS
75). Diabetologia,2006,49:1761- 1769.
[24 Durbin RJ.Thiazolidinedione therapy in the prevention/ delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Meta,2004,6:280- 285.
[25] Nissen SE ,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.NEngl J Med,2007,356:2457- 2471.
[26]Home PD,Phil D,Pocock SJ,et al.Rosiglitazone evaluation for cardiovascular outcomes - an interim analysis. N Engl J Med,2007,[Epub ahead of print]
来源:中国心血管病研究 作者:沈振海 陆昀 方宁远